

VI Literaturverzeichnis

1. Maurer, CA, Zgraggen, K, et al. Pancreatic carcinoma. Optimizing therapy by adjuvant and neoadjuvant therapy?. *Zentralbl Chir* 1999; 124:401-7.
2. Tannapfel, A, Wittekind, C, et al. Ductal adenocarcinoma of the pancreas. Histopathological features and prognosis. *Int J Pancreatol* 1992; 12:145-52.
3. Friess, H, Kleeff, J, et al. Surgical standard therapy for cancer of the pancreas. *Chirurg* 2003; 74:183-90.
4. Woutersen, RA, Appel, MJ, et al. Dietary fat and carcinogenesis. *Mutat Res* 1999; 443:111-27.
5. Roebuck, BD. Dietary fat and the development of pancreatic cancer. *Lipids* 1992; 27:804-6.
6. Sakorafas, GH, Tsiotou, AG, et al. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. *Cancer Treat Rev* 2000; 26:29-52.
7. Lillemoe, KD. Current management of pancreatic carcinoma. *Ann Surg* 1995; 221:133-48.
8. Haycox, A, Lombard, M, et al. Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer. *Aliment Pharmacol Ther* 1998; 12:937-48.
9. Murr, MM, Sarr, MG, et al. Pancreatic cancer. *CA Cancer J Clin* 1994; 44:304-18.
10. Bardeesy, N, DePinho, RA. Pancreatic cancer biology and genetics. *Nat Rev Cancer* 2002; 2:897-909.
11. Meryn, S. Pancreatic carcinoma--epidemiology and risk factors. *Wien Klin Wochenschr* 1994; 106:694-7.
12. Bohmig, M, Wiedenmann, B, et al. Therapy of pancreatic adenocarcinoma. *Med Klin* 1999; 94:614-25.
13. Andren-Sandberg, A, Dervenis, C, et al. Etiologic links between chronic pancreatitis and pancreatic cancer. *Scand J Gastroenterol* 1997; 32:97-103.
14. Hunstad, DA, Norton, JA. Management of pancreatic carcinoma. *Surg Oncol* 1995; 4:61-74.
15. Li, D. Molecular epidemiology of pancreatic cancer. *Cancer J* 2001; 7:259-65.

16. Rode, J. The pathology of pancreatic cancer. *Baillieres Clin Gastroenterol* 1990; 4:793-813.
17. Schäfer, R. *Pathologie* 1995.
18. Jiang, WG, Bryce, RP, et al. Essential fatty acids: molecular and cellular basis of their anti-cancer action and clinical implications. *Crit Rev Oncol Hematol* 1998; 27:179-209.
19. Bockman, DE, Guo, J, et al. Origin and development of the precursor lesions in experimental pancreatic cancer in rats. *Lab Invest* 2003; 83:853-9.
20. Pellegata, NS, Sessa, F, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. *Cancer Res* 1994; 54:1556-60.
21. Almoguera, C, Shibata, D, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. *Cell* 1988; 53:549-54.
22. Cerny, WL, Mangold, KA, et al. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. *Cancer Res* 1992; 52:4507-13.
23. Sakorafas, GH, Lazaris, A, et al. Oncogenes in cancer of the pancreas. *Eur J Surg Oncol* 1995; 21:251-3.
24. Smit, VT, Boot, AJ, et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. *Nucleic Acids Res* 1988; 16:7773-82.
25. Wanebo, HJ, Glicksman, AS, et al. Pancreatic cancer symposium: epidemiology, etiology, pathogenesis, and therapy. *Pancreas* 1995; 10:217-21.
26. Yokoyama, M, Yamanaka, Y, et al. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. *Anticancer Res* 1994; 14:2477-83.
27. Naumann, M, Savitskaia, N, et al. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. *Gastroenterology* 1996; 110:1215-24.
28. Ruggeri, BA, Huang, L, et al. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. *Cancer* 1997; 79:700-16.

29. Friess, H, Berberat, P, et al. Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. *J Mol Med* 1996; 74:35-42.
30. Gouma, DJ, van Dijkum, EJ, et al. Are there indications for palliative resection in pancreatic cancer? *World J Surg* 1999; 23:954-9.
31. Roder, JD, Rosch, T, et al. Pancreatic carcinoma - preoperative diagnosis and indications for surgery. *Chirurg* 1994; 65:225-31.
32. Minniti, S, Bruno, C, et al. Sonography versus helical CT in identification and staging of pancreatic ductal adenocarcinoma. *J Clin Ultrasound* 2003; 31:175-82.
33. Camacho, D, Reichenbach, D, et al. Value of laparoscopy in the staging of pancreatic cancer. *Jop* 2005; 6:552-61.
34. Spiteller, G. Are lipid peroxidation processes induced by changes in the cell wall structure and how are these processes connected with diseases? *Med Hypotheses* 2003; 60:69-83.
35. Gloor, B, Todd, KE, et al. Diagnostic workup of patients with suspected pancreatic carcinoma: the University of California-Los Angeles approach. *Cancer* 1997; 79:1780-6.
36. Brizi, MG, Natale, L, et al. Staging of pancreatic ductal adenocarcinoma with spiral CT and MRI. *Rays* 2001; 26:151-9.
37. Hanbidge, AE. Cancer of the pancreas: the best image for early detection--CT, MRI, PET or US? *Can J Gastroenterol* 2002; 16:101-5.
38. Hermanek, P, Wittekind, C. Residual tumor (R) classification and prognosis. *Semin Surg Oncol* 1994; 10:12-20.
39. Evans, DB, Lee, JE, et al. Advances in the diagnosis and treatment of adenocarcinoma of the pancreas. *Cancer Treat Res* 1997; 90:109-25.
40. Wenger, FA, Jacobi, CA, et al. Gastrointestinal quality of life after duodenopancreatectomy in pancreatic carcinoma. Preliminary results of a prospective randomized study: pancreatoduodenectomy or pylorus-preserving pancreatoduodenectomy. *Chirurg* 1999; 70:1454-9.
41. Ott, K, Bottcher, K, et al. Does the new UICC classification allow better prognostic assessment for ductal pancreatic carcinoma?. *Chirurg* 2000; 71:189-95.
42. Yeo, CJ, Abrams, RA, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. *A*

- prospective, single-institution experience. *Ann Surg* 1997; 225:621-33; discussion 33-6.
43. Berlin, JD, Adak, S, et al. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). *Oncology* 2000; 58:215-8.
 44. Berlin, JD, Rothenberg, ML. Chemotherapeutic advances in pancreatic cancer. *Curr Oncol Rep* 2003; 5:219-26.
 45. El-Rayes, BF, Philip, PA. A review of systemic therapy for advanced pancreatic cancer. *Clin Adv Hematol Oncol* 2003; 1:430-4.
 46. Burris, HA, 3rd, Moore, MJ, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997; 15:2403-13.
 47. Sezgin, C, Karabulut, B, et al. Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. *Scand J Gastroenterol* 2005; 40:1486-92.
 48. Clayton, AJ, Mansoor, AW, et al. A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: is this a strategy still worth pursuing? *Pancreas* 2006; 32:51-7.
 49. Moore, MJ. Brief communication: a new combination in the treatment of advanced pancreatic cancer. *Semin Oncol* 2005; 32:5-6.
 50. Burris, HA, 3rd. Recent updates on the role of chemotherapy in pancreatic cancer. *Semin Oncol* 2005; 32:S1-3.
 51. Reni, M, Cordio, S, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. *Lancet Oncol* 2005; 6:369-76.
 52. Wilkowski, R, Thoma, M, et al. Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer - feasible and effective. *Strahlenther Onkol* 2003; 179:78-86.
 53. Maheshwari, V, Moser, AJ. Current management of locally advanced pancreatic cancer. *Nat Clin Pract Gastroenterol Hepatol* 2005; 2:356-64.
 54. Beger, HG, Rau, B, et al. Treatment of pancreatic cancer: challenge of the facts. *World J Surg* 2003; 27:1075-84.

55. Lim, JE, Chien, MW, et al. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. *Ann Surg* 2003; 237:74-85.
56. Link, KH, Gansauge, F, et al. Palliative and adjuvant regional chemotherapy in pancreatic cancer. *Eur J Surg Oncol* 1997; 23:409-14.
57. Wenger, FA, Kilian, M, et al. Effects of octreotide on liver metastasis and intrametastatic lipid peroxidation in experimental pancreatic cancer. *Oncology* 2001; 60:282-8.
58. Fogar, P, Greco, E, et al. Killer genes in pancreatic cancer therapy. *Cell Mol Biol (Noisy-le-grand)* 2005; 51:61-76.
59. Tseng, JF, Mulligan, RC. Gene therapy for pancreatic cancer. *Surg Oncol Clin N Am* 2002; 11:537-69.
60. Wenger, FA, Peter, F, et al. Prognosis factors in carcinoma of the head of the pancreas. *Dig Surg* 2000; 17:29-35.
61. Friess, H, Isenmann, R, et al. Prognosis in pancreatic carcinoma. *Ther Umsch* 1996; 53:401-7.
62. Gebhardt, C, Meyer, W, et al. Prognostic factors in the operative treatment of ductal pancreatic carcinoma. *Langenbecks Arch Surg* 2000; 385:14-20.
63. Warszawski, N, Link, KH, et al. Effect of therapy on survival of patients with pancreatic carcinoma. *Strahlenther Onkol* 1999; 175:315-9.
64. Benassai, G, Mastroilli, M, et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. *J Surg Oncol* 2000; 73:212-8.
65. Henne-Bruns, D, Vogel, I, et al. Surgery for ductal adenocarcinoma of the pancreatic head: staging, complications, and survival after regional versus extended lymphadenectomy. *World J Surg* 2000; 24:595-601; discussion -2.
66. Beyers, EC, Emken, EA. Metabolites of cis,trans, and trans,cis isomers of linoleic acid in mice and incorporation into tissue lipids. *Biochim Biophys Acta* 1991; 1082:275-84.
67. Banni, S, Angioni, E, et al. Decrease in linoleic acid metabolites as a potential mechanism in cancer risk reduction by conjugated linoleic acid. *Carcinogenesis* 1999; 20:1019-24.

68. Cesano, A, Visonneau, S, et al. Opposite effects of linoleic acid and conjugated linoleic acid on human prostatic cancer in SCID mice. *Anticancer Res* 1998; 18:1429-34.
69. Hawkins, RA, Sangster, K, et al. Apoptotic death of pancreatic cancer cells induced by polyunsaturated fatty acids varies with double bond number and involves an oxidative mechanism. *J Pathol* 1998; 185:61-70.
70. Ritskes-Hoitinga, J, Meijers, M, et al. Effects of two dietary fat levels and four dietary linoleic acid levels on mammary tumor development in Balb/c-MMTV mice under ad libitum feeding conditions. *Nutr Cancer* 1996; 25:161-72.
71. Rose, DP, Connolly, JM. Stimulation of growth of human breast cancer cell lines in culture by linoleic acid. *Biochem Biophys Res Commun* 1989; 164:277-83.
72. Rose, DP. Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies. *Am J Clin Nutr* 1997; 66:1513S-22S.
73. Shultz, TD, Chew, BP, et al. Differential stimulatory and inhibitory responses of human MCF-7 breast cancer cells to linoleic acid and conjugated linoleic acid in culture. *Anticancer Res* 1992; 12:2143-5.
74. Appel, MJ, van Garderen-Hoetmer, A, et al. Effects of dietary linoleic acid on pancreatic carcinogenesis in rats and hamsters. *Cancer Res* 1994; 54:2113-20.
75. Wenger, FA, Kilian, M, et al. Does alpha-linolenic acid in combination with linoleic acid influence liver metastasis and hepatic lipid peroxidation in BOP-induced pancreatic cancer in Syrian hamsters? *Prostaglandins Leukot Essent Fatty Acids* 2000; 62:329-34.
76. Kelly, GS. Conjugated linoleic acid: a review. *Altern Med Rev* 2001; 6:367-82.
77. Belury, MA. Inhibition of carcinogenesis by conjugated linoleic acid: potential mechanisms of action. *J Nutr* 2002; 132:2995-8.
78. Sebedio, JL, Juaneda, P, et al. Metabolites of conjugated isomers of linoleic acid (CLA) in the rat. *Biochim Biophys Acta* 1997; 1345:5-10.
79. Belury, MA. Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. *Annu Rev Nutr* 2002; 22:505-31.
80. Pariza, MW, Park, Y, et al. The biologically active isomers of conjugated linoleic acid. *Prog Lipid Res* 2001; 40:283-98.

81. Ip, C, Scimeca, JA, et al. Conjugated linoleic acid. A powerful anticarcinogen from animal fat sources. *Cancer* 1994; 74:1050-4.
82. Whigham, LD, Cook, ME, et al. Conjugated linoleic acid: implications for human health. *Pharmacol Res* 2000; 42:503-10.
83. Visonneau, S, Cesano, A, et al. Conjugated linoleic acid suppresses the growth of human breast adenocarcinoma cells in SCID mice. *Anticancer Res* 1997; 17:969-73.
84. Sebedio, JL, Gnaedig, S, et al. Recent advances in conjugated linoleic acid research. *Curr Opin Clin Nutr Metab Care* 1999; 2:499-506.
85. Liew, C, Schut, HA, et al. Protection of conjugated linoleic acids against 2-amino-3-methylimidazo[4,5-f]quinoline-induced colon carcinogenesis in the F344 rat: a study of inhibitory mechanisms. *Carcinogenesis* 1995; 16:3037-43.
86. Hubbard, NE, Lim, D, et al. Reduction of murine mammary tumor metastasis by conjugated linoleic acid. *Cancer Lett* 2000; 150:93-100.
87. Ip, C, Singh, M, et al. Conjugated linoleic acid suppresses mammary carcinogenesis and proliferative activity of the mammary gland in the rat. *Cancer Res* 1994; 54:1212-5.
88. Sies, H. Strategies of antioxidant defense. *Eur J Biochem* 1993; 215:213-9.
89. Cheeseman, KH. Mechanisms and effects of lipid peroxidation. *Mol Aspects Med* 1993; 14:191-7.
90. Wilhelm, J. Metabolic aspects of membrane lipid peroxidation. *Acta Univ Carol Med Monogr* 1990; 137:1-53.
91. Gonzalez, MJ. Lipid peroxidation and tumor growth: an inverse relationship. *Med Hypotheses* 1992; 38:106-10.
92. Lawrence, GW, Foran, P, et al. Insights into a basis for incomplete inhibition by botulinum toxin A of Ca²⁺-evoked exocytosis from permeabilised chromaffin cells. *Toxicology* 2002; 181-182:249-53.
93. Pour, PM, Runge, RG, et al. Current knowledge of pancreatic carcinogenesis in the hamster and its relevance to the human disease. *Cancer* 1981; 47:1573-89.
94. Pour, P, Gingell, R, et al. Carcinogenicity of N-nitrosomethyl(2-oxopropyl)amine in Syrian hamsters. *Cancer Res* 1980; 40:3585-90.

95. Pour, P, Salmasi, S, et al. Carcinogenicity of N-nitrosobis(2-hydroxypropyl)amine and N-nitrosobis(2-oxopropyl)amine in MRC rats. *J Natl Cancer Inst* 1979; 63:181-90.
96. Pour, P, Althoff, J. The effect of N-nitrosobis(2-oxopropyl)amine after oral administration to hamsters. *Cancer Lett* 1977; 2:323-6.
97. Pour, P, Althoff, J, et al. A potent pancreatic carcinogen in Syrian hamsters: N-nitrosobis(2-oxopropyl)amine. *J Natl Cancer Inst* 1977; 58:1449-53.
98. Pour, P, Mohr, U, et al. Pancreatic neoplasms in an animal model: morphological, biological, and comparative studies. *Cancer* 1975; 36:379-89.
99. Fujii, H, Egami, H, et al. Pancreatic ductal adenocarcinomas induced in Syrian hamsters by N-nitrosobis(2-oxopropyl)amine contain a c-Ki-ras oncogene with a point-mutated codon 12. *Mol Carcinog* 1990; 3:296-301.
100. Schmied, BM, Ulrich, A, et al. In vitro pancreatic carcinogenesis. *Ann Oncol* 1999; 10 Suppl 4:41-5.
101. Takiyama, Y, Egami, H, et al. Expression of human tumor-associated antigens in pancreatic cancer induced in Syrian hamsters. *Am J Pathol* 1990; 136:707-15.
102. Egami, H, Takiyama, Y, et al. Comparative studies on expression of tumor-associated antigens in human and induced pancreatic cancer in Syrian hamsters. *Int J Pancreatol* 1990; 7:91-100.
103. Visser, CJ, Bruggink, AH, et al. Overexpression of transforming growth factor-alpha and epidermal growth factor receptor, but not epidermal growth factor, in exocrine pancreatic tumours in hamsters. *Carcinogenesis* 1996; 17:779-85.
104. Meijers, M, van Garderen-Hoetmer, A, et al. Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters. *Carcinogenesis* 1990; 11:2223-6.
105. Paglia, DE, Valentine, WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. *J Lab Clin Med* 1967; 70:158-69.
106. Beauchamp, C, Fridovich, I. Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. *Anal Biochem* 1971; 44:276-87.
107. Lowry, OH, Rosebrough, NJ, et al. Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951; 193:265-75.

108. Esterbauer, H, Striegl, G, et al. Continuous monitoring of in vitro oxidation of human low density lipoprotein. *Free Radic Res Commun* 1989; 6:67-75.
109. Ohkawa, H, Ohishi, N, et al. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal Biochem* 1979; 95:351-8.
110. Janero, DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. *Free Radic Biol Med* 1990; 9:515-40.
111. Kilian, M, Mautsch, I, et al. Influence of conjugated vs. conventional linoleic acid on liver metastasis and hepatic lipidperoxidation in BOP-induced pancreatic cancer in Syrian hamster. *Prostaglandins Leukot Essent Fatty Acids* 2002; 67:223-8.
112. Albright, CD, Klem, E, et al. Breast cancer cell-targeted oxidative stress: enhancement of cancer cell uptake of conjugated linoleic acid, activation of p53, and inhibition of proliferation. *Exp Mol Pathol* 2005; 79:118-25.
113. Appel, MJ, Woutersen, RA. Dietary fish oil (MaxEPA) enhances pancreatic carcinogenesis in azaserine-treated rats. *Br J Cancer* 1996; 73:36-43.
114. Begin, ME, Ells, G, et al. Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. *J Natl Cancer Inst* 1986; 77:1053-62.
115. Begin, ME, Ells, G, et al. Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. *J Natl Cancer Inst* 1988; 80:188-94.
116. Birt, DF, Julius, AD, et al. Enhancement of pancreatic carcinogenesis in hamsters fed a high-fat diet ad libitum and at a controlled calorie intake. *Cancer Res* 1989; 49:5848-51.
117. Birt, DF, Salmasi, S, et al. Enhancement of experimental pancreatic cancer in Syrian golden hamsters by dietary fat. *J Natl Cancer Inst* 1981; 67:1327-32.
118. Carroll, KK, Braden, LM. Dietary fat and mammary carcinogenesis. *Nutr Cancer* 1984; 6:254-9.
119. Cornelius, AS, Yerram, NR, et al. Cytotoxic effect of cis-parinaric acid in cultured malignant cells. *Cancer Res* 1991; 51:6025-30.
120. Gonzalez, MJ, Schemmel, RA, et al. Effect of dietary fat on growth of MCF-7 and MDA-MB231 human breast carcinomas in athymic nude mice: relationship

- between carcinoma growth and lipid peroxidation product levels. *Carcinogenesis* 1991; 12:1231-5.
121. Heukamp, I, Gregor, JI, et al. Influence of Different Dietary Fat Intake on Liver Metastasis and Hepatic Lipid Peroxidation in BOP-Induced Pancreatic Cancer in Syrian Hamsters. *Pancreatology* 2005; 6:96-102.
 122. Merendino, N, Loppi, B, et al. Docosahexaenoic acid induces apoptosis in the human PaCa-44 pancreatic cancer cell line by active Reduced glutathione extrusion and lipid peroxidation. *Nutr Cancer* 2005; 52:225-33.
 123. Pariza, MW. Dietary fat and cancer risk: evidence and research needs. *Annu Rev Nutr* 1988; 8:167-83.
 124. Pariza, MW, Ha, YL. Newly recognized anticarcinogenic fatty acids. *Basic Life Sci* 1990; 52:167-70.
 125. Rose, DP. Dietary fatty acids and cancer. *Am J Clin Nutr* 1997; 66:998S-1003S.
 126. Schonberg, S, Krokan, HE. The inhibitory effect of conjugated dienoic derivatives (CLA) of linoleic acid on the growth of human tumor cell lines is in part due to increased lipid peroxidation. *Anticancer Res* 1995; 15:1241-6.
 127. Shultz, TD, Chew, BP, et al. Inhibitory effect of conjugated dienoic derivatives of linoleic acid and beta-carotene on the in vitro growth of human cancer cells. *Cancer Lett* 1992; 63:125-33.
 128. Belury, MA. Conjugated dienoic linoleate: a polyunsaturated fatty acid with unique chemoprotective properties. *Nutr Rev* 1995; 53:83-9.
 129. Das, UN, Begin, ME, et al. Polyunsaturated fatty acids augment free radical generation in tumor cells in vitro. *Biochem Biophys Res Commun* 1987; 145:15-24.
 130. Ip, MM, Masso-Welch, PA, et al. Conjugated linoleic acid inhibits proliferation and induces apoptosis of normal rat mammary epithelial cells in primary culture. *Exp Cell Res* 1999; 250:22-34.
 131. O'Shea, M, Stanton, C, et al. Antioxidant enzyme defence responses of human MCF-7 and SW480 cancer cells to conjugated linoleic acid. *Anticancer Res* 1999; 19:1953-9.
 132. Roebuck, BD, Longnecker, DS, et al. Carcinogen-induced lesions in the rat pancreas: effects of varying levels of essential fatty acid. *Cancer Res* 1985; 45:5252-6.

133. van den Berg, JJ, Cook, NE, et al. Reinvestigation of the antioxidant properties of conjugated linoleic acid. *Lipids* 1995; 30:599-605.
134. Sammon, AM. Maize meal, non-esterified linoleic acid, and endemic cancer of the esophagus--preliminary findings. *Prostaglandins Other Lipid Mediat* 1999; 57:167-71.
135. Kimura, Y. Carp oil or oleic acid, but not linoleic acid or linolenic acid, inhibits tumor growth and metastasis in Lewis lung carcinoma-bearing mice. *J Nutr* 2002; 132:2069-75.
136. Wenger, FA, Jacobi, CA, et al. Does dietary alpha-linolenic acid promote liver metastases in pancreatic carcinoma initiated by BOP in Syrian hamster? *Ann Nutr Metab* 1999; 43:121-6.
137. Roebuck, BD, Yager, JD, Jr., et al. Dietary modulation of azaserine-induced pancreatic carcinogenesis in the rat. *Cancer Res* 1981; 41:888-93.
138. Roebuck, BD, Yager, JD, Jr., et al. Promotion by unsaturated fat of azaserine-induced pancreatic carcinogenesis in the rat. *Cancer Res* 1981; 41:3961-6.
139. Lafrenie, R, Shaughnessy, SG, et al. Cancer cell interactions with injured or activated endothelium. *Cancer Metastasis Rev* 1992; 11:377-88.
140. Hill, GE, Whitten, CW. The role of the vascular endothelium in inflammatory syndromes, atherogenesis, and the propagation of disease. *J Cardiothorac Vasc Anesth* 1997; 11:316-21.
141. Kent, RS, Diedrich, SL, et al. Regulation of vascular prostaglandin synthesis by metabolites of arachidonic acid in perfused rabbit aorta. *J Clin Invest* 1983; 72:455-65.
142. Schimke, I, Griesmacher, A, et al. Effects of reactive oxygen species on eicosanoid metabolism in human endothelial cells. *Prostaglandins* 1992; 43:281-92.
143. Benzie, IF. Lipid peroxidation: a review of causes, consequences, measurement and dietary influences. *Int J Food Sci Nutr* 1996; 47:233-61.
144. Heukamp, I, Kilian, M, et al. Impact of polyunsaturated fatty acids on hepato-pancreatic prostaglandin and leukotriene concentration in ductal pancreatic cancer-Is there a correlation to tumour growth and liver metastasis? *Prostaglandins Leukot Essent Fatty Acids* 2006.

145. Chow, CK. Nutritional influence on cellular antioxidant defense systems. *Am J Clin Nutr* 1979; 32:1066-81.
146. Balasenthil, S, Saroja, M, et al. Of humans and hamsters: comparative analysis of lipid peroxidation, glutathione, and glutathione-dependent enzymes during oral carcinogenesis. *Br J Oral Maxillofac Surg* 2000; 38:267-70.
147. Sanchez-Perez, Y, Carrasco-Legleu, C, et al. Oxidative stress in carcinogenesis. Correlation between lipid peroxidation and induction of preneoplastic lesions in rat hepatocarcinogenesis. *Cancer Lett* 2005; 217:25-32.
148. Marnett, LJ. Oxy radicals, lipid peroxidation and DNA damage. *Toxicology* 2002; 181-182:219-22.
149. Pariza, MW, Park, Y, et al. Conjugated linoleic acid and the control of cancer and obesity. *Toxicol Sci* 1999; 52:107-10.
150. Gavino, VC, Gavino, G, et al. An isomeric mixture of conjugated linoleic acids but not pure cis-9, trans-11-octadecadienoic acid affects body weight gain and plasma lipids in hamsters. *J Nutr* 2000; 130:27-9.
151. Basu, S, Smedman, A, et al. Conjugated linoleic acid induces lipid peroxidation in humans. *FEBS Lett* 2000; 468:33-6.
152. Ip, C, Chin, SF, et al. Mammary cancer prevention by conjugated dienoic derivative of linoleic acid. *Cancer Res* 1991; 51:6118-24.
153. Ip, C, Briggs, SP, et al. The efficacy of conjugated linoleic acid in mammary cancer prevention is independent of the level or type of fat in the diet. *Carcinogenesis* 1996; 17:1045-50.
154. Ip, C, Scimeca, JA. Conjugated linoleic acid and linoleic acid are distinctive modulators of mammary carcinogenesis. *Nutr Cancer* 1997; 27:131-5.
155. Kim, HK, Kim, SR, et al. Dietary conjugated linoleic acid reduces lipid peroxidation by increasing oxidative stability in rats. *J Nutr Sci Vitaminol (Tokyo)* 2005; 51:8-15.
156. Bartsch, H, Hietanen, E, et al. Carcinogenic nitrosamines: free radical aspects of their action. *Free Radic Biol Med* 1989; 7:637-44.
157. Loeppky, RN, Li, YE. Nitrosamine activation and detoxication through free radicals and their derived cations. *IARC Sci Publ* 1991:375-82.
158. Wenger, FA, Kilian, M, et al. Effects of Celebrex and Zylflo on BOP-induced pancreatic cancer in Syrian hamsters. *Pancreatology* 2002; 2:54-60.

159. Reich, R, Martin, GR. Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. *Prostaglandins* 1996; 51:1-17.
160. Karmali, RA. Eicosanoids in neoplasia. *Prev Med* 1987; 16:493-502.
161. Damtew, B, Spagnuolo, PJ. Tumor cell-endothelial cell interactions: evidence for roles for lipoxygenase products of arachidonic acid in metastasis. *Prostaglandins Leukot Essent Fatty Acids* 1997; 56:295-300.
162. Plescia, OJ, Racis, S. Prostaglandins as physiological immunoregulators. *Prog Allergy* 1988; 44:153-71.
163. Odeleye, OE, Watson, RR, et al. Dietary polyunsaturated fatty acid promote peroxidation and its possible role in the promotion of cancer. *Adv Exp Med Biol* 1991; 283:789-91.
164. Jimenez de Asua, L, Otto, AM, et al. The stimulation of the initiation of DNA synthesis and cell division in Swiss mouse 3T3 cells by prostaglandin F2 alpha requires specific functional groups in the molecule. *J Biol Chem* 1983; 258:8774-80.
165. Nakazawa, I, Iwaizumi, M, et al. A difference in prostaglandin-producing ability between cancer cells metastasized into liver and kidney. *Tohoku J Exp Med* 1991; 165:299-304.
166. Takahashi, M, Furukawa, F, et al. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. *Carcinogenesis* 1990; 11:393-5.
167. Ding, XZ, Iversen, P, et al. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. *Biochem Biophys Res Commun* 1999; 261:218-23.
168. Wenger, FA, Kilian, M, et al. Effects of Celebrex and Zylflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters. *Clin Exp Metastasis* 2002; 19:681-7.
169. Cheeseman, KH, Collins, M, et al. Studies on lipid peroxidation in normal and tumour tissues. The Novikoff rat liver tumour. *Biochem J* 1986; 235:507-14.
170. Cheeseman, KH, Emery, S, et al. Studies on lipid peroxidation in normal and tumour tissues. The Yoshida rat liver tumour. *Biochem J* 1988; 250:247-52.
171. Dianzani, MU. Lipid peroxidation and cancer. *Crit Rev Oncol Hematol* 1993; 15:125-47.

172. Liu, KL, Belury, MA. Conjugated linoleic acid reduces arachidonic acid content and PGE2 synthesis in murine keratinocytes. *Cancer Lett* 1998; 127:15-22.
173. Li, Y, Watkins, BA. Conjugated linoleic acids alter bone fatty acid composition and reduce ex vivo prostaglandin E2 biosynthesis in rats fed n-6 or n-3 fatty acids. *Lipids* 1998; 33:417-25.